Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)

INTRODUCTION: Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tamura, Yuichi, Ono, Tomohiko, Fukuda, Keiichi, Satoh, Toru, Sasayama, Shigetake
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2013
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3680653/
https://ncbi.nlm.nih.gov/pubmed/23653230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-013-0029-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares